J. H. Schulte

Targeting MYCN upregulates L1CAM tumor antigen in MYCN-dysregulated neuroblastoma to increase CAR T cell efficacy

This paper shows that high MYCN levels in neuroblastoma reduce L1CAM expression, limiting CAR T cell efficacy, and that inhibiting MYCN with MLN8237 restores L1CAM and enhances CAR T cell activity.

IGF2BP1 induces high-risk neuroblastoma and forms a druggable feedforward loop with MYCN promoting 17q oncogene expression

This paper identifies a druggable feedforward loop between IGF2BP1 and MYCN in high-risk neuroblastoma that promotes oncogene expression and relapse, suggesting combined targeting as a therapeutic strategy.

Intercellular extrachromosomal DNA copy number heterogeneity drives cancer cell state diversity

The paper investigates how ecDNA copy number heterogeneity affects gene expression and transcriptional states in neuroblastoma cells using single-cell DNA and RNA sequencing.

Elimusertib outperforms standard of care chemotherapy in preclinical patient-derived pediatric solid tumor models

This paper evaluates elimusertib's preclinical efficacy in pediatric solid tumor models, finding it outperforms standard chemotherapy, especially in alveolar rhabdomysarcoma.

Neuroblastoma signalling models unveil combination therapies targeting feedback-mediated resistance

This study identifies feedback-mediated resistance to MEK inhibitors in neuroblastoma and shows that combining MEK with RAF or IGFR inhibitors can overcome resistance.

Exploiting a PAX3-FOXO1-induced synthetic lethal ATR dependency for rhabdomyosarcoma therapy

This study identifies ATR as a synthetic lethal target in PAX3-FOXO1-driven rhabdomyosarcoma, showing ATR inhibition enhances PARP inhibitor efficacy and is tolerated in patients.

Enhancer hijacking determines intra- and extrachromosomal circular MYCN amplicon architecture in neuroblastoma

The paper identifies two distinct MYCN amplicon structures in neuroblastoma, showing how enhancer hijacking compensates for loss of local regulatory elements.

MYCN-induced metabolic rewiring creates novel therapeutic vulnerabilities in neuroblastoma

This study shows that MYCN overexpression in neuroblastoma cells rewires metabolism, creating vulnerabilities that can be targeted with metabolic inhibitors.

Circulating microRNA biomarkers for metastatic disease in neuroblastoma patients

This study identifies 9 miRNAs associated with metastatic neuroblastoma by analyzing serum miRNome in patient cohorts and xenografted mice.